优化和优先考虑儿童药物治疗内脏莱什曼病的治疗方法
Tiziana Masini1, Ana Nilce Silveira Maia-Elkhoury2, Dinesh Mondal3
1World Health Organization, Research for Health Department, Science Division, Geneva, Switzerland.
Frontiers in pediatrics
|September 22, 2025
概括
内脏莱什曼病 (VL) 不成比例地影响儿童. 专家们优先考虑了改善的米尔特福辛和安福特里辛B配方用于儿科VL治疗.
科学领域:
- 被忽视的热带疾病被忽视的热带疾病
- 寄生虫学的寄生虫学
- 儿科药理学 儿科药理学
背景情况:
- 内脏莱什曼病 (VL) 是一种致命的寄生虫病,全球超过50%的病例发生在15岁以下的儿童中.
- 脊髓炎与贫困,营养不良和免疫抑制有关,增加了儿科的脆弱性.
- 目前的VL治疗方法是不理想的,特别是对于儿科患者.
研究的目的:
- 确定和优先考虑儿童内脏莱什曼病药物的最佳配方.
- 为满足儿科患者在内脏莱什曼病治疗中的特殊需求.
主要方法:
- 在2023年召开全球儿科药物优化 (PADO) 对VL的练习.
- 聚集了60多名专家来审查和优先考虑VL药物配方.
- 考虑到最近药物开发和剂量策略的进展.
主要成果:
- 优先考虑20mg的得分,可分散的密尔特福辛药片配方.
- 优先考虑安二乙的口服固体剂型.
- 将LXE408列入未来儿科调查的观察名单.
结论:
- 在PADO实践中,确定了改善儿科VL治疗的关键配方.
- 目前正在努力促进优先的米尔特福辛配方的通用制造.
- 建议及早启动对LXE408等新型化合物的儿科研究,以确保患有VL的儿童及时获得创新.
相关概念视频
Pharmacokinetics in Pediatric Patients: Drug Excretion
212
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
212
Pharmacokinetics in Pediatric Patients: Drug Metabolism
195
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
195
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
246
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
246
Pharmacokinetics in Pediatric Patients: Drug Distribution
254
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
254
Drug Dosing: Infants and Children
256
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
256
Factors Affecting Drug Response: Overview
3.0K
When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.0K


